Worldwide Commercialisation of ETSYL

AI SummaryClose X

BSF Enterprise PLC has entered into a worldwide exclusive commercialisation and supply partnership with SCHAKAU Managementberatung GmbH for its bioactive peptide, ETSYL®, in the luxury cosmetics and skincare sectors. This legally binding agreement grants SCHAKAU global rights for an initial 10-year term, contingent on achieving volume targets, with SCHAKAU allocating €300,000 for market development, clinical substantiation, and regulatory compliance. BSF will supply ETSYL® under a structured volume schedule, generating commercial manufacturing margins for its subsidiary, and will share net licensing income 50:50 with SCHAKAU after deducting compliance and patent costs, while BSF retains 100% intellectual property ownership. Initial raw material supply revenues are anticipated within the first 12 months.

Disclaimer*

UK 100

Latest directors dealings